75% ORR in maintenance therapy in multiple myeloma patients

• Patients with MM have a median survival of at least 10 years, and despite improvements in prognosis, almost all patients will eventually relapse
• Ixazomib is an oral proteasome inhibitor (PI) approved for patients who have received at least 1 previous therapy for MM
• A total of 71 patients with newly diagnosed MM were observed after response plateauing between April 2018 and April 2020. The overall response rate (ORR) was 81.7%, including 34 patients (47.9%) with a very good partial response rate or better (≥VGPR) after induction therapy. The ORR was transformed to 74.6% including 39 patients of ≥VGPR (54.9%) after maintenance therapy

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: DEC2021BR001